Views
8 years ago

Psicofarmacología 7

  • Text
  • Borderline
  • Psychiatry
Revista Latinoamericana de Psiquiatría

Referencias

Referencias BibliogrÆficas 1. Adolphs R: The human amygdala and emotion. The Neuroscientist 1999; 5: 125-137. 2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC, American Psychiatric Association, 1994. 3. Arnold M: Memory and the brain. New Jersey, Lawrence Elrbaum Associates, 1984; 90-103. 4. Asberg M, Traksman L, Thoren P: 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry 1976; 33: 1193-1197. 5. Beck J, van der Kolk B A: Reports of childhood incest and current behavior of chronically hospitalized psychotic women. Am J Psychiatry 1987; 144: 1474-1476. 6. Bremner J D, Krystal J H, Charney D S, Southwick S M: Neural mechanisms in dissociative amnesia for childhood abuse: relevance to the current controversy surrounding the "false memory syndrome". Am J Psychiatry 1996; (festschrift supple) 153: 71-82. 7. Coccaro E, Siever L, Klar H, Maurer G, Cochrane K, Cooper T, Mohs R, Davis K: Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry 1989; 46: 587-599. 8. Coccaro E, Siever L, Owen K, Davis K: Serotonin in mood and personality disorders. Edited by Coocaro E, Murphy D. Washington DC, American Psychiatric Press 1990; 69-99. 9. Coccaro E: Impulsive agression and central sero- 18 // PSICOFARMACOLOGÍA tonergic system function in humans: an example of a dimensional behavior relationship. Int Clin Psychopharmacol 1992; 7: 3-12. 10. Coccaro E, Siever L: The neuropsychopharmacology of personality disorders. In Psychopharmacology the fourth generation of progress. Edited by Bloom F, Kupfer D. New York, Raven Press 1994; 1567-1581. 11. Coccaro E, Kavoussi R: Fluoxetine and impulsive agressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54: 1081- 1088. 12. Coccaro E, Kavoussi R, Cooper T, Ferris C, Hauger R: Central serotonin activity and agression inverse relationship with prolactine response to d- fenfluramine but not CSF 5- HIAA concentration, in human subjects. Am J Psychiatry 1997; 154: 1430-1435. 13. Coccaro E, Kavoussi R, Cooper T, Ferris C, Hauger R: Cerebrospinal fluid vasopressin levels correlate with agression and serotonin function in personality- disordered subjects. Arch Gen Psychiatry 1998; 55: 708-714. 14. Coccaro E: Neurotransmitter function in personality disorders. In Biology of personality disorders. Edited by Silk K. Washington DC, American Psychiatric Press 1998; 1-20. 15. Co hen D, Lu na M: Tras tor no lí mi te de la per so - na li dad. Re vi sión de as pec tos clí ni cos, psi co di ná - mi cos y del tra ta mien to far ma co ló gi co. Re vis ta Ar - gen ti na de far ma co lo gía clí ni ca 1995; 2: 105-111. 16. Cohen D: Experiencias Adversas Tempranas, Procesamiento de las Emociones y Regulación de Afectos en Patología Borderline. Actas del XVI Congreso Argentino de Psiquiatría y I Congreso Internacional de Salud Mental APSA, Mar del Plata, Marzo de 2000. 17. Cornelius J R, Soloff P, Perel J, Ulrich R: Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26: 151-154. 18. Cornelius J R, Soloff P, Perel J: A preliminary trial of fluoxetine in refractory borderline patients J Clin Psychopharmacol 1991; 11: 116-120. 19. Depue R A: neurobiological framework for the structure of personality and emotions: implications for personality disorders. Edited by Clarkin,J, Lenzenweger M. New York, The Guilford Press 1996; 347-390. 20. de Vegvar M L, Siever L, Trestman R: Impulsivity and serotonin in borderline personality disorder. In Biological and neurobehavioral studies of borderline personality disorders. Edited by Silk K. Washington DC. American Psychiatric Press 1994; 23-41. 21. Fyer M, Frances A, Sullivan T, Hurt S, Clarkin J: Comorbidity of borderline personality disorder. Arch Gen Psychiatry 1988; 45: 348-352. 22. Gabbard G: Psychodynamic. Psychiatry in the "decade of the brain". Am J Psychiatry 1992; 149: 991-998. 23. Garbutt J, Loosen P, Tipermas A, Prange A J: The TRH test in patients with borderline personality disorder. Psychiatry Res 1983; 9: 107-113. 24. Gardner D, Cowdry R: Pharmacotherapy of borderline personality disorder: a review. Psychopharmacology Bulletin 1989; 25:515-523. 25. George A, Soloff P: Schizotypal symptoms in patients with borderline personality disorders. Am J Psychiatry 1986; 143: 212-215. 26. Grossman R, Yehuda R, Siever L: The dexamethasone suppression test and glucocorticoid receptors in borderline personality disorder. In Psychobiology of posttraumatic stress disorder. Edited by Yehuda R, Mc Farlane A. Ann N Y Acad Sci 1997; 821: 459-465. 27. Gunderson J G, Elliot G R: The interface between borderline personality disorder and affective disorder. Am J Psychiatry 1985; 142: 277- 288. 28. Gunderson J G, Phillips K A: A current view of the interface between borderline personality disorder and depression. Am J Psychiatry 1991; 148: 967-975. 29. Gunderson J G, Zanarini M C: Current overview of the borderline diagnosis. J Clin Psychiatry 1987; 48 [8 suppl]: 5-11. 30. Gunderson J G, Sabo A N: The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry 1993; 150: 19-27. 31. Herman J L, van der Kolk B A: Traumatic antecedents of borderline personality disorder In: Psychological Trauma. Edited by van der Kolk, BA. Washington, DC: American Psychiatric Press 1987; 111-127. 32. Herman J, Perry Ch, van der Kolk B A: Childhood trauma in borderline personality disorder. Am J Psychiatry 1989; 146: 490-495. 33. Hollander E, Stein D, Concetta M, DeCaria M, Cohen L, Saoud J. y col: Serotonergic sensitivity in borderline personality disorder: preliminary finding. Am J Psychiatry 1994; 151: 277-280. 34. Kaufman J, Birmaher B, Perel J, Dahl R E, Moreci P, Nelson B, Wells W, Ryan N D: The corticotrophin-releasing hormone challenge in depressed abused, depressed nonabused, and normal control children. Biol Psychiatry 1997; 42: 669-679. 35. Kavoussi R J, Liu J, Coccaro E F: An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55: 137-141. 36. Koenisberg H, Kaplan R, Gilmore M, Cooper A: The relationship between syndrome and personality disorder in DSM- III: experience with 2.642 patients. Am J Psychiatry 1985; 142: 207-212. 37. Kutcher S, Blacwood D, Gaskell D, Muir W, Clair D M: Auditory P300 does not differentiate borderline personality disorder from schizotypal personality disorder. Biol Psychiatry 1989; 26: 766- 774. 38. KLahmeyer H W, Reynolds C F, Kupfer D, King R: Biologic markers in borderline personality disorder: a review. J Clin Psychiatry 1989; 50: 217- 225. 39. Links P S, Boiago I, Huxley G, Steiner M, Mitton J E: Sexual abuse and biparental failure as etiologic models in borderline personality disorder. Edited by Links, P. Family environment and borderline personality disorder. Washington DC: American Psychiatric Press 1984. 40. Lucas P, Gardner D, Wolkowitz O, Cowdry R: Dysphoria associated with methylphenidate infusion in borderline personality disorder. Am J Psychiatry 1987; 144: 1577-1579. 41. Markovitz P, Calabrese J, Schulz S, Meltzer H: Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148: 1064-1067. 42. Mc Namara E, Reynolds Ch, Soloff P, Rossi A, Spiker D, Coble P: EEG sleep evaluation of depression in borderline patients. Am J Psychiatry 1984; 141: 182-186. 43. Nielsen D, Goldman D, Virkkunen M, Tokola R, Rawlings, Linnoila, M: Suicidality and 5-hydorxyindoleacetic acid concentration associated with a tryptophan hydroxiylase polymorphism. Arch Gen Psychiatry 1994; 51: 34-38. 44. Norden M J: Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 885-893. 45. Paris J, Frank H: Perceptions of parental bonding in borderline patients. Am J Psychiatry 1989; 146: 1489-1499. 46. Paris J, Zweig-Frank H: A critical review of the role of childhood sexual abuse in the etiology of borderline personality disorder. Can J Psychiatry 1992; 37: 125-128. 47. Paris J: The classification of personality disorders should be routed in biology. J Personal Disord 2000; 14: 127-136. 48. Post R M, Uhde T, Putnam F W, Ballanger J C, Berretini W H: Kindling and carbamazepine in affective illness. J Nerv Ment Dis 1982; 170: 717-731. 49. Post R M: Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010. 50. Post R M, Weiss R B: The neurobiology of treatment resistant mood disorders. Edited by Bloom F, Kupfer D. Psychopharmacology the fourth generation of progress. New York: Raven Press 1994; 1151-1170. 51. Rosenblum L A, Coplan J D, Friedman S, Bassof T, Gorman J M, Andrews M W: Adverse early experiences affect noradrenergic and serotonergic functioning in adult primates. Biol Psychiatry 1994; 35: 221-227. 52. Siever L, Davis K A: psychobiological perspective on the personality disorders. Am J Psychiatry 1991; 148: 1647-1658. 53. Siever L: Biological factors in schizotypal personality disorders. Acta Psychiatr Scand 1994; 90 (suppl,384): 45-50. 54. Siever L, New A, Kirrane R, Sherie N, Koenisberg H, Grossman R: New biological strategies for personality disorders. In Biology of personality disorders. Edited by Silk K. Washington DC, American Psychiatric Press 1998; 27-56. 55. Silk K, Lohr N, Cornell D, Harel T, Saakvitne K, Zis A, Buttenheim M C: The dexamethasone suppression test in borderline and nonborderline affective patients. Edited by Mc Glashan T. The borderline current empirical research. Washington DC: American Psychiatric Press 1985; 101-115. 56. Silva H, Jerez S, Paredes A, Salvo J, Rentería P, Ramirez A, Montes C: Fluoxetine in the treatment of borderline personality disorder. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25: 391-395. 57. Soloff P, George M, Nathan S: The dexamethasone suppression test in patients with borderline personality disorders. Am J Psychiatry 1982 139: 1621-1623. 58. Steinberg B, Trestman R, Siever L: The cholinergic and noradrenergic neurotransmitter systems and affective instability in borderline personality disorder. Edited by Silk K. Biological and Neurobehavioral Studies of Borderline Personality Disorder. Washington, DC: American Psychiatric Press 1994; 41-63. 59.Steiner M, Links P: Biological markers in borderline personality disorder: an overview. Can J Psychiatry 1988; 33: 350-354. 60. Stern A: Psychoanalytic investigation of and therapy in the borderline group of neuroses. The Psychoanal Q 1938; 7: 467-489. 61. Sternbach H, Fleming J, Extein I, Potash A L C, Gold M: The dexamethasone suppression and tyrotrophin-releasing hormone test in depressed borderline patients. Psychoneuroendocrinology 1983; 9: 107-113. 62. Stone M: Etiology of borderline personality disorder. Psychobiological factors contributing to an underlying irritability. Edited by Paris J. Borderline personality disorder etiology and treatment. Washington DC: American Psychiatric Press 1993; 87-103 63. Suomi S J: Effect of imipramine treatment of separation-induced social disorders in Rhesus monkeys. Arch General Psychiatry 1978; 35: 321-325. 64. Teicher M, Ito Y, Glod C, Schiffer F, Gelbard H: Early abuse, limbic system dysfunction, and borderline personality disorder. Edited by Silk K. Biological and neurobehavioral studies of borderline personality disorder. Washington DC: American Psychiatric Press 1994; 177-209. 65. Terr L: Childhood traumas : an outline and overview. Am J Psychiatry 1991; 148: 10-20. 66. Van Reekum R, Conway C A, Gansler D, White R, Bachman D L: Neurobehavioral study of borderline personality disorder. J Psychiatry Neurosci 1993; 18: 121-129. 67. van Reekum R, Links P, Boiago I: Constitutional factors in borderline personality disorder: genetics, brain dysfunction, and biological markers. Edited by Paris J. Borderline Personality disorder etiology and treatment. Washington DC: American Psychiatric Press 1993; 13-39. 68. Verkes R J, van der Mast R C, Kerkho J F M, Fekkes D, Hengveld M, Tuyl J P, van Kempen G: Platelet serotonin, monoamine oxidase activity, and [3H] paroxetine binding related to impulsive suicide attempts and borderline personality disorder. Biol Psychiatry 1998; 43: 740-746. 69. Yehuda R, Southwick S, Perry B, Giller E: Altered platelet alfa adrenergic receptor binding sites in borderline personality disorder. Am J Psychiatry 1990; 147:1014-1017. 70. Yehuda R, Southwick S, Perry B, Giller E:. Peripheral catecholamine alterations in borderline personality disorder. Edited by Silk, K. Biological and neurobehavioral studies of borderline personality disorder. Washington, DC: American Psychiatric Press 1994; 63-91. 71. Zanarini M, Williams A, Lewis R, Bradford Reich S, Vera S, Marino M, Levin A, Yong L: Reported pathological childhood experiences associated with the development of borderline personality disorders. Am J Psychiatry 1997; 154: 1101-1106. 72. Zweig-Frank H, Paris J: Parents emotional neglect and overprotection according to the recollections of patients with borderline personality disorder. Am J Psychiatry 1991; 148: 648-651.

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015